Mel Davis Pickett
About Mel Davis Pickett
Mel Davis Pickett is a Principal Scientist at Bristol Myers Squibb in Seattle, WA, with over 14 years of expertise in Flow Cytometry and Cell-Based Potency assays. He has a strong commitment to patient safety and public health, leading the development of innovative medicines across multiple therapeutic areas.
Title
Mel Davis Pickett holds the position of Principal Scientist at Bristol Myers Squibb in Seattle, WA.
Company
Mel Davis Pickett is currently employed by Bristol Myers Squibb, where they operate as a Principal Scientist. Bristol Myers Squibb is known for its work in developing innovative medicines across multiple therapeutic areas including oncology, hematology, immunology, cardiovascular, and neuroscience.
Education and Expertise
Mel Davis Pickett achieved a Certificate in Biostatistics from the University of Washington, where they studied Mathematical Statistics and Probability in 2012. Prior to that, Pickett earned both a BS and BA in Cell and Molecular Biology & Chemistry from The Evergreen State College from 2004 to 2008. With over 14 years of expertise in Flow Cytometry and Cell-Based Potency assays, Pickett is proficient in technical writing for Test Methods, SOPs, and Reports, and is knowledgeable about ICH and USP regulations and guidelines for assay development and strategy consistent with filings.
Professional Experience
Before becoming a Principal Scientist at Bristol Myers Squibb, Mel Davis Pickett worked in several other prestigious institutions. They served as a Research Technician II at Benaroya Research Institute from 2012 to 2014, a Research Scientist/Engineer II at the University of Washington from 2011 to 2012, and a Research Technician at Fred Hutchinson Cancer Research Center from 2008 to 2011.
Innovations and Collaborations
Mel Davis Pickett has led the development of flow cytometry panels that interrogate the phenotype and function of gene-modified T cell drug products. Additionally, Pickett engages in translational medicine, bridging the gap between laboratory research and patient care. They are actively involved in the development of Risk Evaluation and Mitigation Strategies (REMS) for medication safety, and administer three legacy Celgene REMS programs. Their work also includes collaborating with academic institutions and research organizations globally to advance scientific knowledge and patient care.
Commitment to Patient Care
Mel Davis Pickett demonstrates a strong commitment to patient safety and public health. They believe in the value of medicines in transforming patient care and support tiered pricing for medicines to enhance treatment access across different regions. Through independent research and clinical trials, Pickett advances scientific knowledge. They are dedicated to transparency in clinical trial data sharing with researchers, clinical trial participants, regulators, and patient advocates.